Study of Cryoablation for Metastatic Lung Tumors

Inclusion Criteria: * Participant must be at least 18 years old. * Participant has signed a written informed consent. * Participant presents with Stage 4 pulmonary metastatic disease with metastatic disease previously confirmed by prior biopsy; or Participant presents with Stage 4 pulmonary metastatic disease previously confirmed on imaging (for example, computerized tomography or CT) with histology proven primary cancer. * Participant has up to 6 local pulmonary metastases targetable by cryoablation. * Targeted index tumor(s) defined as intra pulmonary or pleural with a maximum size of 3.5 cm, measured in the longest cross-sectional dimension. * The target index tumor(s) is determined (by CT images) to be in a location where cryoablation is technically achievable based on the proximity of adjacent organs/ structures and is greater than 0.5 cm from any critical organ/structure (possibly achieved with additional maneuvers such as iatrogenic pneumothorax or hydrodissection). * Karnofsky Performance Scale (KPS) score greater than or equal to 60. * Platelet count greater than 50,000/millimeters (mm)\^3 within 8 weeks prior to initial cryoablation procedure. * International Normalized Ratio (INR) less than 1.5 within 8 weeks prior to initial cryoablation procedure. * Participant has a life expectancy of greater than 3 months. Exclusion Criteria: * Participant's index tumor(s) is primary lung cancer. * Participant has uncontrollable primary or metastatic disease outside of the lung. * Participant is unable to lie flat or has respiratory distress at rest. * Participant has a coagulopathy or bleeding disorder which is uncontrolled. * Absolute Neutrophil Count (ANC) \<1000 within 8 weeks prior to initial cryoablation procedure. * Participant has evidence of active systemic, pulmonary, or pericardial infection. * Participant has a debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment or follow up. * Participant is currently participating in other experimental studies that could affect the primary endpoint (for example, experimental chemotherapy regimen).